Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001628280-18-003199
Filing Date
2018-03-15
Accepted
2018-03-14 17:44:10
Documents
3
Effectiveness Date
2018-03-15

Document Format Files

Seq Description Document Type Size
1 DEFA14A 2018 ADDITIONAL DEFINITIVE PROXY MATERIALS a2018additionaldefinitivep.htm DEFA14A 44345
2 cumberlandlogo.jpg GRAPHIC 12534
3 internetimage.jpg GRAPHIC 8352
  Complete submission text file 0001628280-18-003199.txt   68932
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000
Type: DEFA14A | Act: 34 | File No.: 001-33637 | Film No.: 18690454
SIC: 2834 Pharmaceutical Preparations